Adherence is a design problem.
People don't fail their treatment. Too often, the treatment fails to fit their lives.
By the Arc editorial team
People don't fail their treatment. Too often, the treatment fails to fit their lives.
The word adherence carries a quiet accusation. To say a patient is non-adherent is to place the failure on them, a lapse of discipline, a lack of seriousness about their own health. It is a comfortable story for everyone except the person living it.
It is also, mostly, wrong.
What the data actually shows
When you look closely at why people stop taking a medicine, the reasons are rarely about motivation. They are about fit. A regimen that demands too much, a side effect that makes an ordinary day worse, a format that is unpleasant or awkward, a cost or complexity that quietly accumulates until it tips.1
Adherence is not a virtue to demand; it is an outcome to design.
Framed that way, the numbers stop being a moral failing and become an engineering brief. If people struggle to take something, the honest question is not why won't they, but what did we ask of them that we shouldn't have.
Designing for real life
A medicine designed for real life anticipates the hard morning, the missed dose, the person who is already unwell and has little patience to spare. It removes steps rather than adding them. When you design for the way people actually live, adherence stops being a battle, and starts being the default.
References
- World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Adherence among patients with chronic disease averages around 50% in developed countries. who.int